Professor Duo Liu, Chief Pharmacist and Doctoral Supervisor at Harbin Medical University Cancer Hospital, is a distinguished pharmaceutical scientist whose research has significantly advanced the fields of pharmacogenomics, pharmacoepidemiology, and precision oncology. With a strong background in medical genetics and pharmacology, Professor Liu has developed a research portfolio that bridges molecular pharmacology with clinical translation, focusing on the genetic mechanisms underlying cancer susceptibility, therapeutic response, and drug resistance. His pioneering contributions include transcriptome-wide association studies identifying novel genetic determinants of pancreatic and prostate cancer risk, as well as investigations into the role of NADPH oxidase polymorphisms and oxidative stress in tumor biology and treatment outcomes. Professor Liu’s scholarly work, published in leading international journals such as Cancer Research, Carcinogenesis, and International Journal of Cancer, has garnered wide recognition for its methodological rigor and clinical relevance. He has successfully led multiple national and institutional research grants, including projects supported by the National Natural Science Foundation of China, and has been honored with several prestigious distinctions for excellence in pharmaceutical sciences and young investigator achievements. As an active member of numerous professional societies, including the Chinese Pharmacological Society and the Anti-Cancer Association of China, Professor Liu contributes to shaping the evolving landscape of cancer pharmacotherapy and drug epidemiology. His collaborations with global research institutions, notably the University of Hawaii Cancer Center, underscore his commitment to advancing international scientific exchange and translational medicine. Through his leadership in clinical pharmacy and mentorship of emerging scientists, Professor Liu continues to drive innovation in personalized cancer treatment and rational drug use, promoting evidence-based healthcare practices that enhance patient outcomes and public health impact worldwide.
Profile: ORCID
Publications
1. Chen, C., Dong, Q., Wang, H., Dong, S., Wang, S., Lin, W., Jia, C., Dong, M., Jin, Y., & Liu, D. (2025, January 8). The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients. Annals of Hematology.
2. Wang, S. F., Dong, S. Q., Dong, Q., Lin, W. X., Dong, M., & Liu, D. (2024). Natural product-induced oxidative stress-synergistic anti-tumor effects of chemotherapeutic agents. Traditional Medicine Research.
3. Dong, S., Chen, C., Di, C., Wang, S., Dong, Q., Lin, W., & Liu, D. (2024, December). The association between NADPH oxidase 2 (NOX2) and drug resistance in cancer. Current Cancer Drug Targets.
4. Liu, D., Bae, Y. E., Zhu, J., Zhang, Z., Sun, Y., Deng, Y., Wu, C., & Wu, L. (2023, December 15). Splicing transcriptome-wide association study to identify splicing events for pancreatic cancer risk. Carcinogenesis.
5. Liu, D., Zhao, T., Zhu, J., Sharapov, S., Tiys, E., & Wu, L. (2023, December 4). Associations between genetically predicted plasma N-glycans and pancreatic cancer risk. All Life.